VSTM vs ABBV vs MRK vs BMY vs CRL

For growth investors, Verastem, Inc.

(VSTM) is the stronger pick with 209. 1% revenue growth year-over-year, versus -0. 9% for Charles River Laboratories International, Inc. (CRL). Bristol-Myers Squibb Company (BMY) offers the better valuation at 16. 5x trailing P/E (9. 0x forward), making it the more compelling value choice. Analysts rate Verastem, Inc. (VSTM) a "Buy" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Bristol-Myers Squibb Company (BMY) is the cheapest at 16.

5x versus AbbVie Inc. at 94. 8x. On forward P/E, Bristol-Myers Squibb Company is actually cheaper at 9. 0x.

Over the past 5 years, AbbVie Inc.

(ABBV) delivered a total return of +121. 1%, compared to -92. 7% for Verastem, Inc. (VSTM). Over 10 years, the gap is even starker: ABBV returned +362. 2% versus VSTM's -75. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), AbbVie Inc.

(ABBV) is the lower-risk stock at 0. 14β versus Verastem, Inc. 's 1. 64β — meaning VSTM is approximately 1104% more volatile than ABBV relative to the S&P 500. On balance sheet safety, Charles River Laboratories International, Inc. (CRL) carries a lower debt/equity ratio of 95% versus 3% for Bristol-Myers Squibb Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Verastem, Inc.

(VSTM) is pulling ahead at 209. 1% versus -0. 9% for Charles River Laboratories International, Inc. (CRL). On earnings-per-share growth, the picture is similar: Bristol-Myers Squibb Company grew EPS 178. 2% year-over-year, compared to -1555. 0% for Charles River Laboratories International, Inc.. Over a 3-year CAGR, VSTM leads at 128. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Merck & Co.

, Inc. (MRK) is the more profitable company, earning 28. 1% net margin versus -677. 6% for Verastem, Inc. — meaning it keeps 28. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MRK leads at 36. 2% versus -550. 3% for VSTM. At the gross margin level — before operating expenses — VSTM leads at 82. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Bristol-Myers Squibb Company (BMY) trades at 9.

0x forward P/E versus 23. 2x for Merck & Co. , Inc. — 14. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for VSTM: 363. 2% to $18. 25.

In this comparison, BMY (4.

3% yield), ABBV (2. 9% yield), MRK (2. 7% yield) pay a dividend. VSTM, CRL do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, AbbVie Inc.

(ABBV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 14), 2. 9% yield, +362. 2% 10Y return). Verastem, Inc. (VSTM) carries a higher beta of 1. 64 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ABBV: +362. 2%, VSTM: -75. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: VSTM is a small-cap high-growth stock; ABBV is a large-cap quality compounder stock; MRK is a large-cap deep-value stock; BMY is a mid-cap deep-value stock; CRL is a small-cap quality compounder stock. ABBV, MRK, BMY pay a dividend while VSTM, CRL do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.